Azenosertib in Uterine Serous Carcinoma: Biomarker Study

This research study is being done to investigate how Azenosertib affects tumor cells of persistent or recurrent uterine serous carcinoma. The name of the study drug involved in this study is: -Azenosertib (a type of Wee1 inhibitor)

Trial Details

NCT ID
NCT06369155
Phase
PHASE2
Sponsor
Joyce Liu, MD
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • Azenosertib
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Participants must have histologically or cytologically confirmed recurrent or persistent uterine serous carcinoma. For the purposes of this study, …
  • Participants must have measurable disease, defined as at least one lesion that can be accurately measured per RECIST 1.1 criteria. See Section 12 f…
  • Participants must have had one prior platinum-based chemotherapy regimen for management of advanced or metastatic uterine serous carcinoma. Partici…
  • Age 18 years or older. Because no dosing or adverse event data are currently available on the use of azenosertib in participants \<18 years of age,…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →